News in brief: First OS improvement in metastatic uveal melanoma; Grant winners announced for Priority-driven Collaborative Cancer Research; Cancer diagnoses to increase by 50%

First treatment to improve OS in metastatic uveal melanoma A novel therapy, tebentafusp, is the first to shown improvements in overall survival (OS) for people with metastatic uveal melanoma, according to investigators presenting results at the American Association for Cancer Research (AACR) Annual Meeting 2021. Tebentafusp is a bispecific consisting of an affinity-enhanced T cell receptor ...

Already a member?

Login to keep reading.

© 2022 the limbic